Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
HLVX HilleVax
12.510
-1.530-10.90%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q1)2021/03/31(FY)2020/12/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
501.64% 8.81M 1117.76% 15.77M 1.47M 1.3M
Selling and administrative expenses
117.28% 2.6M 344.48% 5.76M -- 1.2M -- 1.3M
-General and administrative expense
117.28% 2.6M 344.48% 5.76M -- 1.2M -- 1.3M
Research and development costs
2226.22% 6.21M -- 10.01M -- 267K -- 0
Operating profit
-501.64% -8.81M -1117.76% -15.77M -1.47M -1.3M
Net non-operating interest income expense
-22766.67% -2.06M -9706.9% -2.84M -9K -29K
Non-operating interest income
-- 6K -- -- -- 0 -- --
Non-operating interest expense
22833.33% 2.06M 9706.9% 2.84M -- 9K -- 29K
Other net income (expense)
-79087.5% -57.02M -10656.61% -83.79M -72K -779K
Gain on sale of security
-- -37.42M -- -25.91M -- -- -- --
Special income (charges)
-- -2.5M -- -37.66M -- 0 -- 0
-Less:Other special charges
-- 2.5M -- 37.66M -- -- -- --
Other non- operating income (expenses)
-23637.5% -17.09M -2496.53% -20.23M -- -72K -- -779K
Income before tax
-4291.14% -67.89M -4769.61% -102.41M -1.55M -2.1M
Income tax
Net income
-4291.14% -67.89M -4769.61% -102.41M -1.55M -2.1M
Net income continuous Operations
-4291.14% -67.89M -4769.61% -102.41M -- -1.55M -- -2.1M
Minority interest income
Net income attributable to the parent company
-4291.14% -67.89M -4769.61% -102.41M -1.55M -2.1M
Preferred stock dividends
Other preferred stock dividends
-48.96M
Net income attributable to common stockholders
-4291.14% -67.89M -2441.56% -53.45M -1.55M -2.1M
Basic earnings per share
-2269.46% -2.2486 -2440.92% -3.28 -0.0949 -0.1291
Diluted earnings per share
-2269.46% -2.2486 -2440.92% -3.28 -0.0949 -0.1291
Dividend per share
Currency Unit
USDUSDUSDUSD
Audit Opinions
--Unqualified Opinion with Explanation----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
CEO: Hershberg M.D., Ph.D., Robert M.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top